Naoki Shinojima

4.4k citations
80 papers · 3.0k indexed · 1 hit paper · h-index 26

Naoki Shinojima

76 papers receiving 3.0k citations

Hit Papers

Prognostic value of epidermal growth factor receptor in p...5362003202620102018100200300400500

Peers

Naoki Shinojima
Comparison fields: 5 of 105
  • Genetics 1.3k
  • Cancer Research 602
  • Oncology 682
  • Neurology 363
  • Epidemiology 720
Replace Antonio Daga with:
Antonio Daga Italy
Andrew M. Donson United States
Meena Gujrati United States
Tatsuya Ozawa Japan
Ugo Orfanelli Italy
Rajeev Vibhakar United States
Anhua Wu China
Paul Mulholland United Kingdom
Boris K. Lin United States
David J. Shields United States
Naoki Shinojima relative to Antonio Daga Italy Antonio Daga's profile →
Citations per field
00.5×3.8×
Antonio Daga · 1×
Citations per year

Countries citing papers authored by Naoki Shinojima

Since Specialization
Citations

This map shows the geographic impact of Naoki Shinojima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Shinojima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Shinojima more than expected).

Fields of papers citing papers by Naoki Shinojima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Shinojima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Shinojima. The network helps show where Naoki Shinojima may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Naoki Shinojima, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Naoki Shinojima Line = papers co-authored together Naoki Shinojima links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 202411
2 20240
3 20241
4 20232
5 20233
6 20224
7 202216
8 201818
9 20181
10 20182
11 201717
12 20154
13 20145
14 201383
15 201165
16 201094
17 2009192
18 200931
19 2008100
20 200481

About Naoki Shinojima

Naoki Shinojima is a scholar working on Genetics, Neurology and Endocrinology, Diabetes and Metabolism, having authored 80 papers that have together received 3.0k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (27 papers), Pituitary Gland Disorders and Treatments (15 papers), Meningioma and schwannoma management (14 papers), CNS Lymphoma Diagnosis and Treatment (12 papers), Lymphoma Diagnosis and Treatment (9 papers), Brain Metastases and Treatment (8 papers), Cancer Cells and Metastasis (7 papers) and Mesenchymal stem cell research (7 papers). The work is most often cited by research in Genetics (1.3k citations), Cancer Research (602 citations) and Oncology (682 citations). Naoki Shinojima has collaborated with scholars based in Japan, United States and Canada. Frequent co-authors include Tomohisa Yokoyama, Seiji Kondo, Jun‐ichi Kuratsu, Yasuko Kondo, Joy Gumin, Frederick F. Lang, Shigetoshi Yano, Hideo Nakamura, Yukitaka Ushio and Masato Kochi. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026